Pharmaceuticals

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

OrganaBio's strategic acquisition of Excellos creates a coast-to-coast manufacturing entity, aiming to de-risk and accelerate the complex cell therapy supply chain.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

ICON plc opens a state-of-the-art San Antonio research unit, aiming to accelerate drug development and improve the patient trial experience.

Benchling launches Model Hub, an integrated platform to democratize AI in biotech, aiming to slash R&D timelines by embedding models into daily workflows.

Private equity firm Thurston Group launches Sensorium Clinical Research, a new network aiming to unify top trial sites and streamline medical innovation.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

The 2026 Giants of Multiple Sclerosis® awards celebrate the multidisciplinary teams shaping the future of MS, from research to rehabilitation.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

A new strategic alliance brings European cGMP-grade vitamin APIs to the U.S., promising to enhance quality and supply reliability for compounding pharmacies.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.